Yükleniyor... / Loading...
This study explores an individualized treatment approach for AML (acute myeloid leukemia, a type of blood cancer). It is observational and can include adults aged 18 or older with relapsed or refractory AML that has not responded to previous treatment. It is a study without an assigned phase and is currently recruiting participants.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative. * Agreement to allow the use of archival tissue from diagnostic tumor biopsies * Age: ≥ 18 years * ECOG ≤ 3 (Appendix A) * Patients with histologically confirmed AML according to ICC or WHO criteria, and * Refractory/relapsed (R/R) to prior treatment with one or more regimens if adverse risk or two or more regimens if favorable/intermediate risk (Appendix B) * Sufficient bone marrow and/or peripheral blood sample (archival or fresh) to run the high throughput screening (HTS; Estimate sufficient if circulating blast count of 5,000 or greater or cellular marrow with greater than or equal to 20% blasts.) Otherwise, * Sufficient cells flushed from bone marrow biopsy, if bone marrow is not aspirable, OR * Extramedullary disease, if it is possible to obtain a fluid or biopsy sample from that location * Expected survival is greater than 100 days. * Fully recovered from the acute toxic effects (except alopecia) to ≤ Grade 1 to prior anti-cancer therapy Exclusion Criteria: * Treatment with any chemotherapeutic agent necessary to control AML burden is permitted between day -18 and -1. * Must not have received or planning to receive live vaccine while being on study * Patients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (FAB class M3-AML) * Active central nervous system (CNS) disease (OK if treated and responding) * Active graft vs host disease (GVHD) * Unstable cardiac disease as defined by one of the following: * Cardiac events such as myocardial infarction (MI) within the past 6 months * Uncontrolled atrial fibrillation or hypertension * Clinically significant uncontrolled illness * Uncontrolled active infection * Females only: Pregnant or breastfeeding * Any other condition or active malignancy that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures. * Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).